The drug, human Apo2L/TRAIL (Apo2L), produced only minimal side effects in the 58 patients being tested in the ongoing Phase I study, reports Roy Herbst, M.D., Ph.D., professor and chief, Section of Thoracic Medical Oncology.
Herbst also says that the agent shrunk tumors in one patient with sarcoma, and seemed to stabilize cancer growth in about 56 percent of the 58 patients, but added that it is too early to adequately assess the benefit of Apo2L, especially since the maximum dose that can treat patients and still be well tolerated has not yet been reached.
"This is an interesting new class of targeted agents, and Apo2L may well prove to be promising as we study it further," says Herbst, who presented safety data on the Phase I clinical trial at the 42nd annual meeting of the American Society of Clinical Oncology.
Patients with a variety of advanced cancers are participating in the clinical trial, which is being conducted at five centers around the country. In preclinical studies, Apo2L selectively induced programmed cell death (also known as apoptosis, or cell suicide) in cancer cells while sparing normal cells. It showed activity in animal models of leukemia, non-small cell lung cancer, melanoma and cancers of the colon, prostate and breast.
The drug is designed to activate pathways inside tumor cells that lead to destruction of these cells.
"Normally, the p53 gene regulates cell suicide in the presence of cell damage, such as that induced by chemotherapy and radiotherapy, but this gene is mutated - and therefore inactivated - in more than half of all cancers. We expect this agent to work even in those patients with mutated p53," Herbst says.
Herbst and hi
'"/>
4-Jun-2006